28011886|t|Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
28011886|a|Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14.6 months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role.
28011886	16	39	glioblastoma multiforme	Disease	MESH:D005909
28011886	97	110	dexamethasone	Chemical	MESH:D003907
28011886	115	128	levetiracetam	Chemical	MESH:D000077287
28011886	130	138	Patients	Species	9606
28011886	153	164	astrocytoma	Disease	MESH:D001254
28011886	168	191	glioblastoma multiforme	Disease	MESH:D005909
28011886	193	196	GBM	Disease	MESH:D005909
28011886	306	318	temozolamide	Chemical	-
28011886	413	416	GBM	Disease	MESH:D005909
28011886	451	464	dexamethasone	Chemical	MESH:D003907
28011886	466	469	DEX	Chemical	MESH:D003907
28011886	475	488	levetiracetam	Chemical	MESH:D000077287
28011886	490	493	LEV	Chemical	MESH:D000077287
28011886	551	558	patient	Species	9606
28011886	597	600	GBM	Disease	MESH:D005909
28011886	606	609	DEX	Chemical	MESH:D003907
28011886	614	617	LEV	Chemical	MESH:D000077287
28011886	690	693	DEX	Chemical	MESH:D003907
28011886	701	704	LEV	Chemical	MESH:D000077287
28011886	708	711	GBM	Disease	MESH:D005909
28011886	Comparison	MESH:D000077287	MESH:D003907
28011886	Negative_Correlation	MESH:D003907	MESH:D005909
28011886	Negative_Correlation	MESH:D000077287	MESH:D005909

